A clinically based protein discovery strategy to identify potential biomarkers of response to anti-TNF-α treatment of psoriatic arthritis

Proteomics - Clinical Applications

Volumn 10, Issue 6, 2016, Pages 645-662

  Collins, Emily S ^a,c   Butt, Aisha Q ^a   Gibson, David S ^b   Dunn, Michael J ^a   Fearon, Ursula ^a,c   van Kuijk, Arno W ^d   Gerlag, Danielle M ^d   Pontifex, Eliza ^c   Veale, Douglas J ^a,c   Tak, Paul P ^d   Fitzgerald, Oliver ^a,c   Pennington, Stephen R ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY OF ULSTER   (United Kingdom)

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Anti TNF ; Biomarkers; Proteomics; Psoriatic arthritis; Synovium

Indexed keywords

ADALIMUMAB; ETANERCEPT; INTERLEUKIN 17; INTERLEUKIN 23; METHOTREXATE; PLACEBO; PREDNISOLONE; PROTEIN DERIVATIVE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIRHEUMATIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PHARMACOLOGICAL BIOMARKER; PROTEOME; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; BIOLOGICAL MONITORING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GEL ELECTROPHORESIS; HUMAN; HUMAN TISSUE; MALE; MEASUREMENT; MIDDLE AGED; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEOMICS; PSORIATIC ARTHRITIS; SYNOVIUM; TREATMENT RESPONSE; YOUNG ADULT; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PILOT STUDY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADALIMUMAB; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; BIOMARKERS, PHARMACOLOGICAL; ETANERCEPT; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; PROTEOME; SYNOVIAL MEMBRANE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84945586504     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201500051     Document Type: Article

References (83)

1. Andrianakos, A., Trontzas, P., Christoyannis, F., Dantis, P. et al., Prevalence of rheumatic diseases in Greece: a cross-sectional population based epidemiological study. The ESORDIG Study. J. Rheumatol. 2003, 30, 1589-1601.
2. Braun, J., Bollow, M., Remlinger, G., Eggens, U. et al., Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum. 1998, 41, 58-67.
3. Haglund, E., Bremander, A. B., Petersson, I. F., Strombeck, B. et al., Prevalence of spondyloarthritis and its subtypes in southern Sweden. Ann. Rheum. Dis. 2011, 70, 943-948.
4. Roux, C. H., Saraux, A., Le Bihan, E., Fardellone, P. et al., Rheumatoid arthritis and spondyloarthropathies: geographical variations in prevalence in France. J. Rheumatol. 2007, 34, 117-122.
5. Saraux, A., Guillemin, F., Guggenbuhl, P., Roux, C. H. et al., Prevalence of spondyloarthropathies in France: 2001. Ann. Rheum. Dis. 2005, 64, 1431-1435.
6. Gladman, D. D., Antoni, C., Mease, P., Clegg, D. O., Nash, P., Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann. Rheum. Dis. 2005, 64(Suppl 2), ii14-ii17.
7. Helmick, C. G., Felson, D. T., Lawrence, R. C., Gabriel, S. et al., Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008, 58, 15-25.
8. Husted, J. A., Thavaneswaran, A., Chandran, V., Gladman, D. D., Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis. J. Rheumatol. 2013, 40, 1349-1356.
9. Khraishi, M., MacDonald, D., Rampakakis, E., Vaillancourt, J., Sampalis, J. S., Prevalence of patient-reported comorbidities in early and established psoriatic arthritis cohorts. Clin. Rheumatol. 2011, 30, 877-885.
10. Lee, S., Mendelsohn, A., Sarnes, E., The burden of psoriatic arthritis: a literature review from a global health systems perspective. PT. 2010, 35, 680-689.
11. Tillett, W., de-Vries, C., McHugh, N. J., Work disability in psoriatic arthritis: a systematic review. Rheumatology 2012, 51, 275-283.
12. Brennan, A., Bansback, N., Nixon, R., Madan, J. et al., Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology 2007, 46, 1345-1354.
13. Emery, P., Breedveld, F. C., Hall, S., Durez, P. et al., Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008, 372, 375-382.
14. de Vlam, K., Gottlieb, A. B., FitzGerald, O., Biological biomarkers in psoriatic disease. A review. J. Rheumatol. 2008, 35, 1443-1448.
15. Mullan, R. H., Matthews, C., Bresnihan, B., FitzGerald, O. et al., Early changes in serum type II collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy. Arthritis Rheum. 2007, 56, 2919-2928.
16. Tak, P. P., A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm. Rheumatology 2012, 51, 600-609.
17. Beygi, S., Lajevardi, V., Abedini, R., C-reactive protein n psoriasis: a review of the literature. J. Eur. Acad. Dermatol. Venereol. 2014, 28, 700-711.
18. Curtis, J. R., van der Helm-van Mil, A. H., Knevel, R., Huizinga, T. W. et al., Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res. 2012, 64, 1794-1803.
19. Eastman, P. S., Manning, W. C., Qureshi, F., Haney, D. et al., Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis. J. Pharm. Biomed. Anal. 2012, 70, 415-424.
20. Ademowo, O. S., Hernandez, B., Collins, E., Rooney, C. et al., Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis. Ann. Rheum. Dis. 2014. doi: 10.1136/annrheumdis-2014-205417.
21. Balakrishnan, L., Bhattacharjee, M., Ahmad, S., Nirujogi, R. S. et al., Differential proteomic analysis of synovial fluid from rheumatoid arthritis and osteoarthritis patients. Clin. Proteomics 2014, 11, 1.
22. Balakrishnan, L., Nirujogi, R. S., Ahmad, S., Bhattacharjee, M. et al., Proteomic analysis of human osteoarthritis synovial fluid. Clin. Proteomics 2014, 11, 6.
23. Cretu, D., Prassas, I., Saraon, P., Batruch, I. et al., Identification of psoriatic arthritis mediators in synovial fluid by quantitative mass spectrometry. Clin. Proteomics 2014, 11, 27.
24. Gibson, D. S., Blelock, S., Curry, J., Finnegan, S. et al., Comparative analysis of synovial fluid and plasma proteomes in juvenile arthritis-proteomic patterns of joint inflammation in early stage disease. J. Proteomics 2009, 72(4):656-676.
25. Gibson, D. S., Finnegan, S., Jordan, G., Scaife, C. et al., Stratification and monitoring of juvenile idiopathic arthritis patients by synovial proteome analysis. J. Proteome Res. 2009, 8, 5601-5609.
26. Morrissey, B., O'Shea, C., Armstrong, J., Rooney, C. et al., Development of a label-free LC-MS/MS strategy to approach the identification of candidate protein biomarkers of disease recurrence in prostate cancer patients in a clinical trial of combined hormone and radiation therapy. Proteomics. Clin. Appl. 2013, 7, 316-326.
27. Sekigawa, I., Yanagida, M., Iwabuchi, K., Kaneda, K. et al., Protein biomarker analysis by mass spectrometry in patients with rheumatoid arthritis receiving anti-tumor necrosis factor-alpha antibody therapy. Clin. Exp. Rheumatol. 2008, 26, 261-267.
28. Sinz, A., Bantscheff, M., Mikkat, S., Ringel, B. et al., Mass spectrometric proteome analyses of synovial fluids and plasmas from patients suffering from rheumatoid arthritis and comparison to reactive arthritis or osteoarthritis. Electrophoresis 2002, 23, 3445-3456.
29. de Seny, D., Fillet, M., Meuwis, M. A., Geurts, P. et al., Discovery of new rheumatoid arthritis biomarkers using the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry ProteinChip approach. Arthritis Rheum. 2005, 52, 3801-3812.
30. Kuhn, E., Wu, J., Karl, J., Liao, H. et al., Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled peptide standards. Proteomics 2004, 4, 1175-1186.
31. Lorenz, P., Ruschpler, P., Koczan, D., Stiehl, P., Thiesen, H. J., From transcriptome to proteome: differentially expressed proteins identified in synovial tissue of patients suffering from rheumatoid arthritis and osteoarthritis by an initial screen with a panel of 791 antibodies. Proteomics 2003, 3, 991-1002.
32. Schulz, M., Dotzlaw, H., Mikkat, S., Eggert, M., Neeck, G., Proteomic analysis of peripheral blood mononuclear cells: selective protein processing observed in patients with rheumatoid arthritis. J. Proteome Res. 2007, 6, 3752-3759.
33. Smith, M. A., Bains, S. K., Betts, J. C., Choy, E. H., Zanders, E. D., Use of two-dimensional gel electrophoresis to measure changes in synovial fluid proteins from patients with rheumatoid arthritis treated with antibody to CD4. Clin. Diagn. Lab. Immunol. 2001, 8, 105-111.
34. Tilleman, K., Van, Beneden K., Dhondt, A., Hoffman, I. et al., Chronically inflamed synovium from spondyloarthropathy and rheumatoid arthritis investigated by protein expression profiling followed by tandem mass spectrometry. Proteomics 2005, 5, 2247-2257.
35. Uchida, T., Fukawa, A., Uchida, M., Fujita, K., Saito, K., Application of a novel protein biochip technology for detection and identification of rheumatoid arthritis biomarkers in synovial fluid. J. Proteome Res. 2002, 1, 495-499.
36. Bo, G. P., Zhou, L. N., He, W. F., Luo, G. X. et al., Analyses of differential proteome of human synovial fibroblasts obtained from arthritis. Clin. Rheumatol. 2009, 28, 191-199.
37. Matsuo, K., Xiang, Y., Nakamura, H., Masuko, K. et al., Identification of novel citrullinated autoantigens of synovium in rheumatoid arthritis using a proteomic approach. Arthritis Res. Ther. 2006, 8, R175.
38. Dwivedi, R. C., Dhindsa, N., Krokhin, O. V., Cortens, J. et al., The effects of infliximab therapy on the serum proteome of rheumatoid arthritis patients. Arthritis Res. Ther. 2009, 11, R32.
39. Koczan, D., Drynda, S., Hecker, M., Drynda, A. et al., Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept. Arthritis Res. Ther. 2008, 10, R50.
40. Kitteringham, N. R., Jenkins, R. E., Lane, C. S., Elliott, V. L., Park, B. K., Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2009, 877, 1229-1239.
41. Lange, V., Picotti, P., Domon, B., Aebersold, R., Selected reaction monitoring for quantitative proteomics: a tutorial. Mol. Syst. Biol. 2008, 4, 222.
42. Lau, T. Y., Collins, B. C., Stone, P., Tang, N. et al., Absolute quantification of toxicological biomarkers by multiple reaction monitoring. Methods. Mol. Biol. 2011, 691, 417-427.
43. Metodieva, G., Greenwood, C., Alldridge, L., Sauven, P., Metodiev, M., A peptide-centric approach to breast cancer biomarker discovery utilizing label-free multiple reaction monitoring mass spectrometry. Proteomics Clin. Appl. 2009, 3, 78-82.
44. Szymanski, D. W., Papanastasiou, M., Melchior, K., Zvonok, N. et al., Mass spectrometry-based proteomics of human cannabinoid receptor 2: covalent cysteine 6.47(257)-ligand interaction affording megagonist receptor activation. J. Proteome Res. 2011, 10, 4789-4798.
45. Addona, T. A., Abbatiello, S. E., Schilling, B., Skates, S. J. et al., Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat. Biotechnol. 2009, 27, 633-641.
46. Picotti, P., Lam, H., Campbell, D., Deutsch, E. W. et al., A database of mass spectrometric assays for the yeast proteome. Nat. Methods 2008, 5, 913-914.
47. Schiess, R., Wollscheid, B., Aebersold, R., Targeted proteomic strategy for clinical biomarker discovery. Mol. Oncol. 2009, 3, 33-44.
48. Jenkins, R. E., Kitteringham, N. R., Hunter, C. L., Webb, S. et al., Relative and absolute quantitative expression profiling of cytochromes P450 using isotope-coded affinity tags. Proteomics 2006, 6, 1934-1947.
49. Jovanovic, M., Reiter, L., Picotti, P., Lange, V. et al., A quantitative targeted proteomics approach to validate predicted microRNA targets in C. elegans. Nat. Methods 2010, 7, 837-842.
50. Lange, V., Malmstrom, J. A., Didion, J., King, N. L. et al., Targeted quantitative analysis of Streptococcus pyogenes virulence factors by multiple reaction monitoring. Mol. Cell. Proteomics 2008, 7, 1489-1500.
51. Picotti, P., Bodenmiller, B., Mueller, L. N., Domon, B., Aebersold, R., Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics. Cell 2009, 138, 795-806.
52. Whiteaker, J. R., Zhang, H., Zhao, L., Wang, P. et al., Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J. Proteome Res. 2007, 6, 3962-3975.
53. Gerlag, D. M., Tak, P. P., How to perform and analyse synovial biopsies. Best Pract. Res. Clin. Rheumatol. 2009, 23, 221-232.
54. van de Sande, M. G., Gerlag, D. M., Lodde, B. M., van Baarsen, L. G. et al., Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials. Ann. Rheum. Dis. 2011, 70, 423-427.
55. Bradford, M. M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
56. Pontifex, E. K., Gerlag, D. M., Gogarty, M., Vinkenoog, M. et al., Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy-a single centre, open-label study. Arthritis Res. Ther. 2011, 13, R7.
57. van Gestel, A. M., Anderson, J. J., van Riel, P. L., Boers, M. et al., ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J. Rheumatol. 1999, 26, 705-711.
58. van Gestel, A. M., Haagsma, C. J., van Riel, P. L., Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 1998, 41, 1845-1850.
59. van Gestel, A. M., Prevoo, M. L., van 't Hof, M. A., van Rijswijk, M. H. et al., Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996, 39, 34-40.
60. van Kuijk, A. W., DeGroot, J., Koeman, R. C., Sakkee, N. et al., Soluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriatic arthritis: effects of adalimumab versus placebo. PloS One 2010, 5(9): e12556.
61. van Kuijk, A. W., Gerlag, D. M., Vos, K., Wolbink, G. et al., A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue. Ann. Rheum. Dis. 2009, 68, 1303-1309.
62. Yan, J. X., Wait, R., Berkelman, T., Harry, R. A. et al., A modified silver staining protocol for visualization of proteins compatible with matrix-assisted laser desorption/ionization and electrospray ionization-mass spectrometry. Electrophoresis 2000, 21, 3666-3672.
63. Grassl, J., Scaife, C., Polden, J., Daly, C. N. et al., Analysis of the budding yeast pH 4-7 proteome in meiosis. Proteomics 2010, 10, 506-519.
64. Maclean, B., Tomazela, D. M., Abbatiello, S. E., Zhang, S. et al., Effect of collision energy optimization on the measurement of peptides by selected reaction monitoring (SRM) mass spectrometry. Anal. Chem. 2010, 82, 10116-10124.
65. MacLean, B., Tomazela, D. M., Shulman, N., Chambers, M. et al., Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 2010, 26, 966-968.
66. Keller, A., Nesvizhskii, A. I., Kolker, E., Aebersold, R., Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal. Chem. 2002, 74, 5383-5392.
67. Picotti, P., Aebersold, R., Domon, B., The implications of proteolytic background for shotgun proteomics. Mol. Cell. Proteomics 2007, 6, 1589-1598.
68. Prakash, A., Piening, B., Whiteaker, J., Zhang, H. et al., Assessing bias in experiment design for large scale mass spectrometry-based quantitative proteomics. Mol. Cell. Proteomics 2007, 6, 1741-1748.
69. Rabilloud, T., Chevallet, M., Luche, S., Lelong, C., Two-dimensional gel electrophoresis in proteomics: past, present and future. J. Proteomics 2010, 73, 2064-2077.
70. Alban, A., David, S. O., Bjorkesten, L., Andersson, C. et al., A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 2003, 3, 36-44.
71. Anderson, N. L., Anderson, N. G., The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1, 845-867.
72. Huttenhain, R., Malmstrom, J., Picotti, P., Aebersold, R., Perspectives of targeted mass spectrometry for protein biomarker verification. Curr. Opin. Chem. Biol. 2009, 13, 518-525.
73. Poste, G., Bring on the biomarkers. Nature 2011, 469, 156-157.
74. Focking, M., Boersema, P. J., O'Donoghue, N., Lubec, G. et al., 2-D DIGE as a quantitative tool for investigating the HUPO Brain Proteome Project mouse series. Proteomics 2006, 6, 4914-4931.
75. Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., Tak, P. P., Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Thera. 2008, 117, 244-279.
76. Scallon, B. J., Moore, M. A., Trinh, H., Knight, D. M., Ghrayeb, J., Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995, 7, 251-259.
77. Mohler, K. M., Torrance, D. S., Smith, C. A., Goodwin, R. G. et al., Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 1993, 151, 1548-1561.
78. Campbell, I. K., Piccoli, D. S., Roberts, M. J., Muirden, K. D., Hamilton, J. A., Effects of tumor necrosis factor alpha and beta on resorption of human articular cartilage and production of plasminogen activator by human articular chondrocytes. Arthritis Rheum. 1990, 33, 542-552.
79. Rosenkranz, M. E., Wilson, D. C., Marinov, A. D., Decewicz, A. et al., Synovial fluid proteins differentiate between the subtypes of juvenile idiopathic arthritis. Arthritis Rheum. 2010, 62, 1813-1823.
80. Smeets, M. B., Fontijn, J., Kavelaars, A., Pasterkamp, G., De Kleijn, D. P., The acute phase protein haptoglobin is locally expressed in arthritic and oncological tissues. Int. J. Exp. Pathol. 2003, 84, 69-74.
81. Swisher, J. F., Khatri, U., Feldman, G. M., Annexin A2 is a soluble mediator of macrophage activation. J. Leukoc. Biol. 2007, 82, 1174-1184.
82. Tagoe, C. E., Marjanovic, N., Park, J. Y., Chan, E. S. et al., Annexin-1 mediates TNF-alpha-stimulated matrix metalloproteinase secretion from rheumatoid arthritis synovial fibroblasts. J. Immunol. 2008, 181, 2813-2820.
83. Yamamoto, M., Okamoto, T., Takeda, K., Sato, S. et al., Key function for the Ubc13 E2 ubiquitin-conjugating enzyme in immune receptor signaling. Nat. Immunol. 2006, 7(9):962-970.